Testing DAOIB with an antioxidant in early memory loss and Alzheimer disease
Tests DAOIB with or without an antioxidant in adults with early dementia.
Plain-language title generated from the registry record
Registry title: Novel Augmentation of DAOIB and Antioxidant for Early Dementia
Key facts
- Where
- Kaohsiung City, TaiwanSee the site
- Phase
- Phase 2
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 50 and 90 years old?
Source: NCT06467539, who can take part
Where in Taiwan
- Chang Gung Memorial HospitalKaohsiung City, TaiwanTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Chang Gung Memorial Hospital
- Trial code
- NCT06467539
- Record updated
- 19 March 2026
- Original description
Previous studies found that some NMDA-enhancing agents were able to improve cognitive function of patients with early-phase dementia. In addition, several drugs with antioxidant properties have been tested in clinical trials for the treatment of dementia too. Whether combined treatment of an NMDA-enhancing agent and a drug with antioxidant property can be better than an NMDA-enhancing agent alone deserves study.Read full original descriptionShow less
Novel Augmentation of DAOIB and Antioxidant for Early Dementia
Previous studies found that some NMDA-enhancing agents were able to improve cognitive function of patients with early-phase dementia. In addition, several drugs with antioxidant properties have been tested in clinical trials for the treatment of dementia too. Whether combined treatment of an NMDA-enhancing agent and a drug with antioxidant property can be better than an NMDA-enhancing agent alone deserves study.
Inclusion: Clinical diagnosis of Alzheimer's disease or mild cognitive impairment; MMSE between 10-26; CDR 1 or 0.5.
Exclusion: Parkinson disease, epilepsy, dementia with psychotic features; Major depressive disorder; Major physical illnesses; Severe visual or hearing impairment; Hachinski Ischemic Score > 4; Substance abuse/dependence.